Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells

European Journal of Pharmacology

Volumn 663, Issue 1-3, 2011, Pages 17-26

  Yang, Tsung Ying ^a,b   Chang, Gee Chen ^b,c,d   Chen, Kun Chieh ^b,d   Hung, Hsiao Wen ^b   Hsu, Kuo Hsuan ^b,d   Sheu, Gwo Tarng ^a,e   Hsu, Shih Lan ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; CDK2; Cyclin A; ERK; Pemetrexed; S phase arrest

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE 3; CYCLIN A; CYCLIN DEPENDENT KINASE 2; FLAVOPIRIDOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEMETREXED; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; ENZYME ACTIVATION; GLUTAMATES; GUANINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; S PHASE; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 79959287068     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.057     Document Type: Article

References (47)

1. Adachi, S., Ito, H., Tamamori-Adachi, M., Ono, Y., Nozato, T., Abe, S., Ikeda, M., Marumo, F., Hiroe, M., 2001. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ. Res. 88, 408-414.
2. Backus, H.H., Pinedo, H.M., Wouters, D., Kuiper, C.M., Jansen, G., van Groeningen, C.J., Peters, G.J., 2000. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol. Res. 12, 231-239.
3. Bock, J.M., Menon, S.G., Sinclair, L.L., Bedford, N.S., Goswami, P.C., Domann, F.E., Trask, D.K., 2007. Celecoxib toxicity is cell cycle phase specific. Cancer Res. 67, 3801-3808. (Pubitemid 46762167)
4. Britten, C.D., Izbicka, E., Hilsenbeck, S., Lawrence, R., Davidson, K., Cerna, C., Gomez, L., Rowinsky, E.K., Weitman, S., Von Hoff, D.D., 1999. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 44, 105-110.
5. Calcabrini, A., Garcia-Martinez, J.M., Gonzalez, L., Tendero, M.J., Ortuno, M.T., Crateri, P., Lopez-Rivas, A., Arancia, G., Gonzalez-Porque, P., Martin-Perez, J., 2006. Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate. Carcinogenesis 27, 1699-1712. (Pubitemid 44288060)
6. Chambard, J.C., Lefloch, R., Pouyssegur, J., Lenormand, P., 2007. ERK implication in cell cycle regulation. Biochim. Biophys. Acta 1773, 1299-1310.
7. Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J.H., Krzakowski, M., Laack, E., Wu, Y.L., Bover, I., Begbie, S., Tzekova, V., Cucevic, B., Pereira, J.R., Yang, S.H., Madhavan, J., Sugarman, K.P., Peterson, P., John, W.J., Krejcy, K., Belani, C.P., 2009. Maintenance pemetrexed plus best supportive care versusplacebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374, 1432-1440.
8. Curtin, N.J., Harris, A.L., Aherne, G.W., 1991. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′- triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 51, 2346-2352.
9. Dai, Y., Grant, S., 2003. Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol. 3, 362-370.
10. Ding, H., Han, C., Guo, D., Wang, D., Chen, C.S., D'Ambrosio, S.M., 2008. OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int. J. Cancer 123, 2923-2930.
11. Gil-Gomez, G., Berns, A., Brady, H.J., 1998. A link between cell cycle and cell death: Bax and Bcl-2modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 17, 7209-7218. (Pubitemid 29002690)
12. Group, N.M.-A.C., 2008. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26, 4617-4625.
13. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., Einhorn, L., Bunn Jr., P.A., 2004. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597.
14. Hsu, Y.L., Kuo, P.L., Lin, L.T., Lin, C.C., 2005. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J. Pharmacol. Exp. Ther. 313, 333-344.
15. Jackson, R.C., 1984. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol. Ther. 25, 61-82.
16. Jiang, W., Wells, N.J., Hunter, T., 1999. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc. Natl. Acad. Sci. U. S. A. 96, 6193-6198.
17. Kastan, M.B., Lim, D.S., 2000. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186.
18. Kim, G.S., Hong, J.S., Kim, S.W., Koh, J.M., An, C.S., Choi, J.Y., Cheng, S.L., 2003. Leptin induces apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal cells. J. Biol. Chem. 278, 21920-21929.
19. Krude, T., Jackman, M., Pines, J., Laskey, R.A., 1997. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell 88, 109-119. (Pubitemid 27180335)
20. Lavin, M.F., Kozlov, S., 2007. ATM activation and DNA damage response. Cell Cycle 6, 931-942. (Pubitemid 46658748)
21. Lu, Z., Xu, S., 2006. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58, 621-631. (Pubitemid 44691463)
22. Mebratu, Y., Tesfaigzi, Y., 2009. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8, 1168-1175.
23. Meijer, L., Borgne, A., Mulner, O., Chong, J.P., Blow, J.J., Inagaki, N., Inagaki, M., Delcros, J.G., Moulinoux, J.P., 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527-536.
24. Meikrantz, W., Gisselbrecht, S., Tam, S.W., Schlegel, R., 1994. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. U. S. A. 91, 3754-3758.
25. Meloche, S., Pouyssegur, J., 2007. The ERK1/2mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239. (Pubitemid 46763017)
26. Min, S.H., Goldman, I.D., Zhao, R., 2008. Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed. Cancer Chemother. Pharmacol. 61, 819-827.
27. Nougarede, R., Della Seta, F., Zarzov, P., Schwob, E., 2000. Hierarchy of S-phase-promoting factors: yeast Dbf4-Cdc7 kinase requires prior S-phase cyclin-dependent kinase activation. Mol. Cell. Biol. 20, 3795-3806.
28. Pandita, T.K., Lieberman, H.B., Lim, D.S., Dhar, S., Zheng, W., Taya, Y., Kastan, M.B., 2000. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 19, 1386-1391. (Pubitemid 30171169)
29. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
30. Peng, Y., Sigua, C.A., Murr, M.M., 2011. Protein kinase C-zeta mediates apoptosis of mouse Kupffer cells via ERK-1/2: a novel mechanism. Surgery 149, 135-142.
31. Ramirez, J.M., Ocio, E.M., San Miguel, J.F., Pandiella, A., 2007. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia 21, 797-804. (Pubitemid 46444565)
32. Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P., Gandara, D., 2008. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3543-3551.
33. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J., Johnson, D.H., 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98.
34. Shaul, Y.D., Seger, R., 2007. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 1773, 1213-1226.
35. Sozmen, M., Tunca, R., Dag Erginsoy, S., 2009. Cyclin A expression is associated with apoptosis and mitosis in murine 3-methylcholanthrene-induced fibrosarcomas. Exp. Toxicol. Pathol. 61, 41-49.
36. Tang, D., Wu, D., Hirao, A., Lahti, J.M., Liu, L., Mazza, B., Kidd, V.J., Mak, T.W., Ingram, A.J., 2002. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710-12717.
37. Teicher, B.A., Alvarez, E., Liu, P., Lu, K., Menon, K., Dempsey, J., Schultz, R.M., 1999. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin. Oncol. 26, 55-62.
38. Teicher, B.A., Chen, V., Shih, C., Menon, K., Forler, P.A., Phares, V.G., Amsrud, T., 2000. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6, 1016-1023.
39. Tekle, C., Giovannetti, E., Sigmond, J., Graff, J.R., Smid, K., Peters, G.J., 2008. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br. J. Cancer 99, 750-759.
40. Tonkinson, J.L., Marder, P., Andis, S.L., Schultz, R.M., Gossett, L.S., Shih, C., Mendelsohn, L.G., 1997. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol. 39, 521-531.
41. Tonkinson, J.L., Worzalla, J.F., Teng, C.H., Mendelsohn, L.G., 1999. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59, 3671-3676. (Pubitemid 29381871)
42. Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C., Paoletti, P., 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636-2644.
43. Wang, X., Martindale, J.L., Holbrook, N.J., 2000. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435-39443.
44. Xiao, D., Singh, S.V., 2002. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 62, 3615-3619. (Pubitemid 34728834)
45. Yam, C.H., Fung, T.K., Poon, R.Y., 2002. Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci. 59, 1317-1326.
46. Yin, H., Subrata, S., Yang, W., Yang, G., 2001. Overexpression of cyclin A leads to S-phase arrested apoptosis. Hua Xi Yi Ke Da Xue Xue Bao 32, 188-190.
47. Yoon, S., Seger, R., 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44. (Pubitemid 43108774)